THE PATH OF PERSONALIZED MEDICINE: REGULATORY PERSPECTIVE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2015, Vol 3, Issue 1
Abstract
Personalized medicine (PM) has become a topic of great interest because of its potential to improve patient care and optimize therapeutic strategy. The way we understand and treat disease is changing rapidly. The traditional form of personalized medicine has been based on the observable manifestations of a disease or treatment, such as a tumour on a mammogram, the appearance of cells under the microscope, etc. But now personalized medicine promises to introduce a new standard of healthcare by using molecular analysis to achieve optimum medical outcomes in the management of a patient’s disease or disease predisposition. PM is providing the right treatment, to the right patient at the right time by using modern biology’s new methods and tools. The objective of this paper is to focus on a realistic scenario for its evolution, and to explore the issues affecting the development and implementation of personalized medicines and various regulatory pathways involved in its regulation. This paper also highlights the roles and applications of personalized medicine. The success of personalized medicine depends on having accurate diagnostic tests that identify patients who can benefit from targeted therapies. The common goal: an integrated policy framework that balances patient, industry and scientific interests without hindering advancement of this tremendously important sector. Through these efforts, we can help ensure that personalized medicine is able to fulfil its promise as rapidly as possible.
Authors and Affiliations
Chitral Kulshreshtha, Venkatesh M P, Pramod Kumar T M
Keywords
Related Articles
- EP ID EP338320
- DOI -
- Views 86
- Downloads 0
ACTD: BRIDGE BETWEEN REGULATORY REQUIREMENTS OF DEVELOPED AND DEVELOPING COUNTRIES
Regulatory Dossier contains data which when submitted to the regulatory authority, provides for the review and ultimate approval of a drug product. Once approved, an applicant may manufacture and market the drug to provi...
A SNAP-SHOT OF FIRST-LINE ART TREATMENT FAILURE CASES FROM MPUMALANGA PROVINCE ON THE DECENTRALISED PHARMACOVIGILANCE PROGRAMME DATABASE
The increase in ART use comes with the inevitable increase in cases of ART treatment failure, especially that patients are living longer on ART. The main objective of this short study was to conduct an interim review of...
FORMULATION AND EVALUATION OF NANOSUSPENSION OF ROSUVASTATIN CALCIUM
Poor water solubility and slow dissolution rate are issues for majority of upcoming and existing biologically active compounds. The aim of present work was to increase the dissolution rate of Rosuvastatin Calcium, a poor...
RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF TELMISARTAN IN BULK AND TABLET DOSAGE FORM
A simple, sensitive, precise and specific reverse phase high performance liquid chromatographic method was developed and validated for the determination of Telmisartan in bulk and tablet dosage forms. It was found that t...
Regulatory requirements for Drug master file in context to Canada and Australia
Drug Master Files are required in most countries as supporting documents for the registration of drug products. DMFs generally contain information pertaining to the chemistry, manufacturing and controls (CMC) sections of...